You are here

Share:

Search Technologies

Showing 1-9 of 9 results found

3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery

Scientists at the National Eye Institute (NEI) have developed a technology for a 3D bioprinting process. Through the process, an artificial blood retinal barrier (BRB) is constructed that may be used as a graft to potentially replace BRB tissues that are lost or damaged in many ocular disorders. The printed tissue structures might be therapeutically useful for grafts or as model systems to test function and physiological responses to drugs or other variables introduced into the system.

RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa

The National Eye Institute (NEI) seek research co-development or licensees for advancing AAV8/9-based therapies for X-linked forms of retinitis pigmentosa (XLRP) caused by mutations in RPGR (retinitis pigmentosa GTPase regulator) or RP2 (retinitis pigmentosa 2) gene.

Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration

Researchers at the National Eye Institute (NEI) have discovered a novel therapeutic strategy of using one or more selective estrogen-receptor modulators (SERMs), which may include the FDA-approved drug, Tamoxifen, for treating retinal degenerative diseases, like retinitis pigmentosa (RP) and age-related degeneration (AMD). SERMs exert their specific protection on photoreceptor degeneration likely by inhibiting microglial activation.

Sterculic Acid Treatment for Choroidal Neovascularization

The National Eye Institute (NEI) Laboratory of Retinal Cell and Molecular Biology is seeking parties interested in licensing use of sterculic acid and its derivatives for the treatment of diseases related to angiogenesis or mediated by 7-ketocholesterol-induced inflammation, in particular, atherosclerosis, age-related macular degeneration, and Alzheimer''s disease.